b-Catenin is a potent oncogenic protein whose cytoplasmic accumulation is a frequent event in cancer cells. The level of b-catenin is regulated by two mechanisms: the adenomatous polyposis coli/Axin/glycogen synthase kinase 3b-dependent degradation pathway and the Siah-1/ Siah interacting protein/Ebi-mediated degradation pathway. In this study, we have investigated the functional significance of p53-inducible human Siah-family protein expression in the regulation of b-catenin activity. We show here by reverse-transcriptase polymerase chain reaction that two mRNA transcripts, designated human Siah-1 and Siah-1L, are generated from the human Siah-1 locus. Interestingly, the expression of Siah-1L was upregulated by p53, whereas human Siah-1 expression was constant. Furthermore, introduction of exogenous Siah-1L protein downregulated b-catenin protein and promoted apoptosis induced by anticancer drugs in cancer cells that lack endogenous p53. Thus, Siah-1L represents a new member of the human Siah family that is induced in response to p53 and plays an important role in the regulation of b-catenin activity in tumor cells. These findings also suggest new strategies for restoring tumor suppressive pathways lost in cancer cells that have suffered p53 inactivation.
Introduction b-Catenin is a multifunctional cytoplasmic protein, which plays an important role in Wnt signalling pathway and in the maintenance of cell-cell adhesion (Provost and Rimm, 1999; Peifer and Polakis, 2000) . It has been demonstrated that cellular b-catenin levels are regulated by two different mechanisms. The first mechanism involves a phosphorylation-dependent pathway. The current model suggests that the Axin and adenomatous polyposis coli (APC) gene products serve as scaffolds to facilitate the phosphorylation of bcatenin by glycogen synthase kinase 3b (GSK3b) (Yost et al., 1996; Hart et al., 1998) . Phosphorylated b-catenin is targeted for ubiquitin-mediated degradation. The second mechanism is a phosphorylation-independent pathway, which is initiated by an increase in Siah-family protein expression. Siah-family proteins interact sequentially with Siah interacting protein (SIP), Skp1, and Ebi (Matsuzawa and Reed, 2001) . Ebi binds directly to bcatenin and initiates a subsequent proteosome-mediated degradation (Matsuzawa and Reed, 2001) .
The Siah-family proteins are the mammalian homologues of the Drosophila Sina protein. The Siah-family proteins bind ubiquitin-conjugating enzymes via an N-terminal RING domain and target other proteins for degradation (Hu et al., 1997b) . The human Siah-1 and Siah-2 genes encode Sina-like proteins (Hu et al., 1997a) . The human Siah-1 gene has two murine homologues, Siah-1a and Siah-1b (Della et al., 1993) . The murine Siah-1b was reported to be a direct transcriptional target of p53 (Fiucci et al., 2004) . Some studies have also suggested that human Siah-1 may act as a downstream effector of p53 (Hu et al., 1997a; Matsuzawa et al., 1998; Roperch et al., 1999; Relaix et al., 2000; Liu et al., 2001; Maeda et al., 2002) . However, the mechanism by which p53 induces human Siah-1 gene is still unclear. Moreover, it is possible to hypothesize that findings in murine may be also found in human Siah-1 gene.
Although aberrant accumulation of b-catenin is a frequent event observed in various human cancers including colorectal, lung, and breast cancers, hepatocellular carcinoma (HCC), and hepatoblastoma (Chung, 2000; Lin et al., 2000; Park et al., 2001; Inagawa et al., 2002) , mutation of APC, Axin, or b-catenin is not commonly found in several human cancers including HCC (de La Coste et al., 1998) . In fact, it has been reported that the b-catenin and Axin are mutated in only about 10 and 7% of HCC, respectively (Satoh et al., 2000; Devereux et al., 2001; Wong et al., 2001 ). These results indicate that the cytoplasmic accumulation of b-catenin is not associated with mutations in b-catenin, Axin, or APC in 35-80% of HCCs. Moreover, aberrant accumulation of b-catenin protein without any evidence of dysfunction in the GSK3b-mediated degradation pathway is not limited to HCCs (Chung, 2000; Lin et al., 2000; Park et al., 2001; Inagawa et al., 2002) . Therefore, it is possible to hypothesize that dysfunction in the Siah-1-mediated degradation pathway may contribute to the accumulation of b-catenin in human cancers.
In this study, we have addressed the mechanism of bcatenin protein regulation in tumor cells by investigating the functional significance of p53-inducible Siah-family protein expression. We demonstrated here a novel Siah-1 variant that is involved in the regulation of bcatenin protein degradation in a p53-dependent manner. Our findings thus provide novel insights into the mechanism of b-catenin accumulation in cancers lacking functional p53.
Results
Siah-1L is upregulated in response to p53 and plays an important role in p53-mediated downregulation of b-catenin
The human Siah-1 gene maps to chromosome 16q12-13 (GeneBank accession number NP_010505.11) and consists of two exons and one long intron (B24 kb) (Figure 1a) . Using an RNase protection assay, we have previously identified an alternative human Siah-1 mRNA variant that was induced by p53 (Matsuzawa et al., 1998) . This mRNA variant contains an additional in-frame ATG start codon (first ATG) upstream of the original ATG (second ATG) (Figure 1a) . Indeed, reverse-transcriptase polymerase chain reaction (RT-PCR) using primers specific for human Siah-1 revealed two different transcripts in MCF7 cells, which have wild-type p53 gene (data not shown). The shorter transcript encoded the human Siah-1 mRNA, while Figure 1 The expression of Siah-1L is induced by p53-mediated signalling. (a) Schematic presentation of the Siah-1L and Siah-1 genes. The Siah-1 gene is shown along with the mRNAs encoding Siah-1L and Siah-1. Splice sites and start and stop positions are shown as lower numbers at their respective genomic nucleotide positions. Ligation of exons 1 and 2 produces the Siah-1 mRNA, whereas inclusion of an extra 48 bp due to an early translation initiation from an ATG codon in the intron produces the Siah-1L mRNA, which encodes a 298-amino-acid protein. The binding sites of the primers used for RT-PCR are outlined. (b) MCF7 cells (p53 wild type) were treated with DOX (1.5 mg/ml). Total RNA was isolated before (0 h) and 6, 12, 24, and 36 h after DOX treatment. RT-PCR was performed using 0.5 mg of each RNA sample as a template and oligonucleotide primer sets specific for Siah-1L (upper panel), Siah-1 (middle panel), and GAPDH (lower panel). (c) Total protein was immediately isolated from MCF7 cells before (0 h) and 6, 12, 24, and 36 h after treatment with DOX (1.5 mg/ml). A 5 mg portion of each protein sample was electrophoresed, blotted, and reacted with antibodies to b-catenin, p53, Siah-1, or a-actin. (d) MCF7 cells were treated with UV irradiation (10 J/m 2 ), and total RNA was isolated immediately before (0 h) and 12 h after UV treatment. RT-PCR was performed using specific primers for Siah-1L (upper panel), Siah-1 (middle panel), and GAPDH (lower panel). (e) MCF7 cells were irradiated at 10 J/m 2 , and total protein was isolated before (0 h) and 12 h after irradiation. A 5 mg portion of each protein sample was analysed by Western blots using anti-b-catenin, antip53, anti-Siah-1, or anti-a-actin antibodies. (f) Hep3B (p53-null) cells were harvested before (0 h) and 6, 12, 24, and 36 h after treatment with DOX (1.0 mg/ml). Total protein was isolated and Western blot analyses were carried out using anti-b-catenin, anti-p53, or anti-aactin. (g) Total RNA was sequentially isolated from Hep3B cells before (0 h) and after DOX treatment (6, 12, 24, and 36 h). RT-PCR was performed using 0.5 mg of each RNA sample and specific primers for Siah-1L, Siah-1, and GAPDH
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A Iwai et al the longer transcript encoded a new variant containing 48 extra nucleotides at the 5 0 end (Figure 1a) . We named the novel longer transcript Siah-1L. To clarify which Siah-1 transcript was actually induced by p53, we further investigated the expression of human Siah-1 transcripts in MCF7 cells after treatment with doxorubicin (DOX; Calbiochem, San Diego, CA, USA), which is known to induce p53 activation. As shown in Figure 1b , an endogenous 897-bp Siah-1L transcript was barely detectable in control cells; however, the expression of Siah-1L mRNA was strongly induced 6-12 h after DOX treatment (Figure 1b, upper panel) . In contrast, the 849-bp Siah-1 mRNA remained unchanged (Figure 1b, middle panel) . The increase in Siah-1L mRNA levels prompted us to examine whether the protein levels changed in response to DOX treatment. Next, we analysed the expression levels of p53, bcatenin, and Siah-1-family proteins. As shown in Figure 1c , p53 protein expression was strongly induced 6 h after treatment with DOX and the expression peaked at 12 h. The level of endogenous b-catenin protein started to decrease 24 h and showed a marked reduction 36 h after treatment. The expression of endogenous Siah-1-family proteins was low in control cells; however, Siah-1L but not Siah-1 was upregulated 12 h after DOX treatment ( Figure 1c, lower panel) .
To further investigate whether Siah-1L was induced in a p53-dependent manner, we examined the expression levels of Siah-family proteins and b-catenin in cells after UV irradiation. As shown in Figure 1d , the Siah-1L transcript increased 12 h after UV irradiation in MCF7 cells; in contrast, UV treatment did not trigger any changes in the level of Siah-1 transcript. Furthermore, Siah-1L protein expression was markedly increased in response to UV treatment, and the elevation of p53 protein and the degradation of b-catenin were also observed at the same time ( Figure 1e) .
Next, we investigated the expression levels of Siah-1L transcript in Hep3B cells, which have been reported to lack both copies of the p53 gene (Lee et al., 2002) . Expression of the p53 and b-catenin proteins was analysed by Western blots after DOX treatment. As expected, the p53 protein was undetectable in lysates derived from control cells and DOX-treated cells ( Figure 1f ). The expression of endogenous b-catenin protein did not change in the presence of DOX (Figure 1f ). The Siah-1 transcript was detectable in control cells and was not changed when the cells were treated with DOX ( Figure 1g , middle panel). In contrast, the Siah-1L mRNA was undetectable in the presence and absence of DOX ( Figure 1g , upper panel). These findings further suggest that Siah-1L is upregulated in response to p53 activity.
To determine whether the induction of Siah-1L expression is specifically dependent on p53, MCF7 and Hep3B cells were transiently transfected with expression plasmids encoding wild-type or mutant p53, and Siah-1-family transcripts were analysed by RT-PCR. As shown in Figure 2a , increased amounts of Siah-1L mRNA were found in p53-expressing MCF7 cells, but not in control cells. Siah-1 mRNA remained unchanged in cells after the overexpression of p53 protein. Mutant p53 did not upregulate the Siah-1L mRNA, and instead decreased its expression (Figure 2a ). To explore the role of Siah-1L in the regulation of b-catenin activity, we analysed the expression of b-catenin protein in cells transfected with wild-type or mutant p53. Levels of b-catenin protein were significantly lower in p53-overexpressing cells compared with both control and p53-mutant-expressing cells (Figure 2b ). Since loss of p53 function is a frequent event in various human cancer cells, we then tested whether Siah-1L could be induced by exogenous p53 in cells that lack functional p53. As shown in Figure 2c , Siah-1L mRNA was significantly upregulated in p53-expressing Hep3B cells, while Siah-1L transcript was undetectable in control and mutant p53-expressing cells. The expression levels of Siah-1 were unchanged in p53-expressing cells compared to control cells (Figure 2c) . Notably, levels of b-catenin protein were markedly decreased in endogenous p53-deficient cells after transfection with the p53 expression plasmid ( Figure 2d ). Next, to clarify whether Siah-1L is responsible for the p53-mediated degradation of b-catenin, we employed the short interfering RNA (siRNA) approach and used an expression plasmid encoding Siah-1 lacking the RING finger domain (pcDNA3-FLAG-Siah-1DRING), which is a dominant-negative form of Siah-1L. We showed the siRNA specific for Siah-1L (siSiah-1L) induced the reduction of the transfected Siah-1L, not Siah-1, in HEK293T cells (Figure 2e ). In contrast, control siRNA (siCTR) did not show any effect of the protein levels of Siah-1L and Siah-1. Moreover, in the p53-transfected cells, siSiah-1L markedly reduced the expression level of endogenous Siah-1L, but not Siah-1 transcript ( Figure 2f ). To examine the protein levels of b-catenin in the Siah-1L knockdown cells, we performed Western blots. Transfection of siSiah-1L had almost rescued the p53-induced degradation of b-catenin (Figure 2g ). However, this recovery of the b-catenin protein levels was not observed in siCTRtransfected cells. We also demonstrated that the protein levels of b-catenin were recovered in the cells cotransfected with expression plasmids encoding FLAG-Siah-1DRING and p53 from the p53-dependent degradation (Figure 2h ). Taken together, these findings suggest that p53 specifically enhances the expression of Siah-1L and is involved in the regulation of b-catenin protein degradation via the expression of Siah-1L.
Siah-1L suppresses Tcf/LEF transcriptional activity and enhances the degradation of b-catenin
To explore the functional significance of p53-inducible Siah-1L expression, we asked whether Siah-1L production affects b-catenin activity in cells. Since b-catenin forms a complex with a member of the T-cell factor (Tcf)/lymphocyte enhancer-binding factor (LEF) family and activated the target genes (Omer et al., 1999) , reporter assays were performed to monitor Tcf/LEFdependent gene expression in the presence or absence of Siah-1L or Siah-1. We used pcDNA3-FLAGSiah-1DRING, which is a dominant-negative form of Siah-1L induced by p53 A Iwai et al Siah-1L, as a negative control. In addition, a reporter plasmid with a mutated Tcf-binding site was also used as a negative control for the reporter assay. As shown in Figure 3a , about a 40-fold augmentation of relative luciferase activity was found in cells transfected with an expression plasmid encoding b-catenin. When Siah-1L was produced in cells, the level of Tcf/LEF transcriptional activity induced by overexpression of b-catenin was markedly decreased compared with that in control cells (Figure 3a) . In contrast, a plasmid encoding Siah-1DRING did not decrease reporter activity, instead slightly upregulated the b-catenin activity. Transcription from the reporter plasmid containing the mutated Tcf/ LEF-binding site was not affected by overexpression of b-catenin or Siah-1L protein. We also found that expressing Siah-1L in cells resulted in a dose-dependent reduction in the relative Tcf/LEF transcriptional activity induced by b-catenin (Figure 3b ). In addition, a marked reduction in the levels of endogenous b-catenin protein was detectable in cells expressing Siah-1L compared to control or Siah-1DRING-expressing cells (Figure 3c ). These findings indicate that Siah-1L regulates Tcf/LEF activity and b-catenin protein levels in cells.
Since a p53-activating stimulus was required for Siah-1L expression, we asked whether Siah-1L could reduce b-catenin activity in Hep3B cells that lack endogenous p53. As shown in Figure 3d , expression of b-catenin protein induced about a 20-fold in Tcf/LEF transcriptional activity. When an expression plasmid encoding Siah-1L was cotransfected, Tcf/LEF activity was reduced almost by half. Moreover, analysis of endogenous b-catenin levels demonstrated that exogenously expressed Siah-1L protein significantly reduced the amount of b-catenin (Figure 3e) . Similar results were observed in H1299 cells, which lack p53 genes (data not shown). Thus, despite the deletion of the endogenous p53 genes, exogenous expression of Siah-1L resulted in the degradation of endogenous b-catenin protein, suggesting a role for Siah-1L as a negative regulator of b-catenin activity.
Mutant b-catenin found in some cancer cells is resistant to Siah-1L-induced protein degradation Mutated b-catenin found in HepG2 cells is known to carry an activating mutation caused by the deletion of amino acids 25-140 (de La Coste et al., 1998) . This mutant b-catenin is known to be resistant to GSK3b-mediated degradation, resulting in an aberrant accumulation of b-catenin (de La Coste et al., 1998). To determine whether Siah-1-family proteins can regulate the activity of mutated b-catenin, we examined the effects of Siah-1L expression on mutant b-catenin protein in HepG2 cells, which have wild-type p53 gene. Expression plasmids encoding wild-type or mutant p53 and pPUR were cotransfected into Hep3B cells, and puromycin (2.0 mg/ml) was added to the medium 24 h after transfection. After 72 h, total protein was isolated and analysed by Western blots using anti-bcatenin (upper panel) or anti-p53 (middle panel) antibodies. (e) HEK293T cells were transfected with the expression plasmids of FLAG-Siah-1L or -Siah-1 with or without siRNA for Siah-1L (siSiah-1L). Cells were cultured for 36 h in the presence of MG 132. Cell lysates were analysed by Western blots using anti-FLAG and anti-a-actin antibodies. siCTR represents a control siRNA. (f) Total RNA was isolated from HEK293T cells transfected with p53 expression plasmids with or without siRNA for Siah-1L (siSiah-1L). Control siRNA-transfected cells (siCTR) were used as a negative control. RT-PCR was performed using specific primers for Siah-1L (upper panel), Siah-1 (middle panel), or GAPDH (lower panel). (g) The siRNA for Siah-1L (siSiah-1L) or control siRNA (siCTR) was transfected in HEK293T cells. After 24 h, cells were transfected with the expression plasmids of Myc-tagged bcatenin (AAAA) with or without p53 expression plasmid and cultured for 36 h. Total protein was isolated from these cells and Western blots were performed using anti-Myc, anti-p53, and antia-actin. (h) Total protein was isolated from HEK293T cells transfected with Myc-tagged b-catenin (AAAA) and p53 expression plasmids with or without FLAG-tagged Siah-1DRING expression plasmid. Cell lysates were analysed by Western blots with antibodies against Myc, p53, FLAG, and a-actin
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As shown in Figure 4a , the endogenous expression of both wild-type and mutant b-catenin proteins was observed in cells. The levels of endogenous p53 protein were markedly increased after DOX treatment ( Figure 4a , middle panel). The amount of Siah-1L mRNA was strongly upregulated in response to DOX, whereas the level of Siah-1 transcript remained unchanged (Figure 4b) . Interestingly, the degradation of wild-type b-catenin protein in HepG2 cells was observed after p53 activation induced by DOX. However, the expression of mutant b-catenin protein remained unchanged (Figure 4a , upper panel) and levels of Tcf/LEF Siah-1L induced by p53 A Iwai et al activity remained unchanged in cells overexpressing Siah-1L or Siah-1 (data not shown). We then investigated the ability of Siah-1L to induce degradation of transiently overexpressed Db-catenin (deleted 25-140) or mutant b-catenin (AAAA). As shown in Figure 4c , both Siah-1L and Siah-1 markedly reduced the levels of wildtype b-catenin and b-catenin (AAAA), while the levels of Db-catenin (deleted 25-140) remained unchanged. Taken together, these results indicate that b-catenin lacking amino acids 25-140 is resistant to Siah-1-dependent degradation pathways.
Siah-1L sensitizes cancer cells to apoptosis induced by anticancer drugs
To explore the functional significance of p53-inducible Siah-1L in tumor cell survival, we evaluated the ability of Siah-1L to promote apoptosis. MCF7 cells were transiently transfected with plasmids encoding Siah-1L, Siah-1, or Siah-1DRING, and cell death was measured 48 h after treatment with DOX. As shown in Figures 5a and b, Siah-1L and Siah-1 enhanced cell death by greater than 50% compared to the control and Siah-1DRING-expressing cells. Interestingly, apoptosissensitizing effects induced by Siah-1L protein were also observed in p53-null cells (Figures 5c and d) . Moreover, similar results were obtained when cell death was induced by cisplatin or UV irradiation in MCF7 and Hep3B cells (data not shown). These data strongly suggest that Siah-1L accelerates cell death induced by anticancer drugs irrespective of the status of endogenous p53 protein.
Discussion
It has been suggested that Siah-1 may act as a downstream effector of p53; however, the 5 0 -flanking region of the Siah-1 gene is known to lack typical TATA or CCAAT boxes and that reporter plasmids containing the promoter region of Siah-1 do not respond to p53 (Maeda et al., 2002) . Recently, the p53-responsive element has been identified upstream of the alternative in-frame ATG start codon located in the intron 1 of the human Siah-1 gene (Matsuzawa et al., unpublished data) . In this study, we demonstrated that a novel isoform belonging to the human Siah-1 family, Siah-1L, was identified as a p53-inducible protein.
Dysfunction of the b-catenin degradation pathway results in aberrant accumulation of b-catenin; this is a frequent event in various human cancers, and the aberrant accumulation of b-catenin is reported to trigger oncogenesis and tumor progression (Chung, 2000; Lin et al., 2000; Park et al., 2001; Inagawa et al., 2002) . However, it has also been shown that aberrant accumulation of b-catenin is not always accompanied by known dysfunction or mutation of the APC, Axin, or b-catenin genes. Recently, Cagatay and Ozturk (2002) demonstrated that aberrant accumulation of b-catenin in tumors is often associated with inactivation of the p53 gene. They also showed that worldwide p53 and b-catenin mutation rates are inversely correlated in HCC (Cagatay and Ozturk, 2002) . These data suggest that inactivation of p53 may be an important cause of aberrant accumulation of b-catenin in cancer cells. However, the molecular mechanism by which p53 regulates b-catenin activity has been unclear. In this study, we have demonstrated that the expression level of Siah-1L is regulated in a p53-dependent manner in cells with wild-type p53. In contrast, in p53-null cells, no induction of Siah-1L was observed after p53-activating stimuli, resulting in the sustained accumulation of bcatenin protein. Moreover, using specific siRNA for Siah-1L, p53-induced degradation of b-catenin was almost rescued. These results suggest that lack of Siah-1L, but not Siah-1, expression in response to p53 may contribute to the aberrant accumulation of b-catenin in cells harboring p53 mutations. It is important to note that overexpression of Siah-1L in p53-null cells led to the degradation of the accumulated endogenous bcatenin protein, indicating that aberrant accumulation of b-catenin can be reversed by exogenously expressed Siah-1-family proteins in cancer cells regardless of p53 status.
b-Catenin with mutations in the GSK3b phosphorylation sites has been observed in various human cancers. For example, mis-sense mutations at codons 32, 34, 37, or 41, which affect the GSK3b phosphorylation sites of b-catenin, were also common in HCC (Wong et al., 2001; Cagatay and Ozturk, 2002) . Siah-family proteins trigger the degradation of b-catenin protein regardless of the GSK3b-mediated phosphorylation of b-catenin. Thus, our data indicate that activation of Siah-1L-dependent b-catenin degradation, including the overexpression of exogenous Siah-1L proteins, may On the other hand, constitutive activation of b-catenin caused by deletions in exons 3 and 4 was found in some human cancers (de La Coste et al., 1998) . Therefore, we must draw attention to the finding that overexpression of Siah-1-family protein had little effect on the degradation of this mutant b-catenin found in HepG2 cells. Further analysis of the Siah-1/SIP/Ebi pathway for b-catenin degradation is necessary to find a strategy to counteract the various types of mutant b-catenin protein.
We have concluded that p53-dependent expression of Siah-1L but not Siah-1 plays an important role in the regulation of b-catenin activity in human tumor cells. These results suggest new strategies for restoring tumor suppressive pathways caused by p53 inactivation.
Materials and methods

Plasmids
The cDNA encoding human Siah-1L was generated by RT-PCR from the mRNA of MCF7 cells treated with DOX using SuperScript II (Invitrogen, San Diego, CA, USA), followed by PCR amplification using the KOD-Plus-DNA polymerase system (TOYOBO, Osaka, Japan) and the following oligonucleotide primers: 5 0 -GACGAATTCATGGTTATAATTAT TTTTCT-3 0 (sense) and 5 0 -GACCTCGAGTCAACACATGG AAATAGTTAC-3 0 (antisense). The resulting PCR fragments were inserted into the EcoRI-XhoI sites of pcDNA3-FLAG (Matsuzawa and Reed, 2001 ). pcDNA3-FLAG-Siah-1 and pcDNA3-FLAG-Siah-1DRING plasmids were constructed by inserting the EcoRI-XhoI fragments from the pcDNA3-MycSiah-1 and pcDNA3-Myc-Siah-1DRING plasmids into the pcDNA3-FLAG vector (Matsuzawa and Reed, 2001 ). pRC-CMV-p53 (wild type) and pRC-CMV-p53 (179Mut) were described previously (Unger et al., 1992) . The expression plasmid encoding b-catenin, pcDNA3-Myc-b-catenin, was described previously (Ueda Y et al., 2001) . The cDNAs encoding various b-catenin mutants were generated by twostep PCR amplification. Briefly, to construct b-catenin (AAAA), which has alanine substitutions at the putative GSK3b phosphorylation sites (serine or threonine amino-acid residues at positions 33, 37, 41, and 45), a DNA fragment encoding amino acids 1-37, a fragment encoding amino acids 33-50, and a fragment encoding amino acids 44-781 were separately PCR amplified with the following primer sets:
0 -TCTAGATTACAGGTCAGTATCAAACC-3 0 . The resulting PCR fragments were mixed and subjected to a second PCR reaction to obtain full-length b-catenin (AAAA) containing BamHI and XbaI sites. To construct Db-catenin (deleted 25-140), which lacks amino acids 25-140, DNA fragments encoding the amino-and carboxyl-terminal regions were separately PCR amplified with primer sets BCAT-fullS and BCAT-25AS (5 0 -GTGACTAACAGCCGCTTTTC-3 0 ) and BCAT-120S (5 0 -GTGTTGTTTTATGCCATTAC-3 0 ) and BCAT-fullAS, respectively. The two PCR products were mixed and subjected to a second PCR reaction to obtain full-length Db-catenin (deleted 25-140) containing BamHI and XbaI sites. These products were subcloned into the BamHI and XbaI sites of the pcDNA3-Myc plasmid (Matsuzawa and Reed, 2001) . The reporter plasmids pTcf7wt-Luc and pTcf7mut-Luc have been described previously (Ueda Y et al., 2001) . All constructs were confirmed by DNA sequencing.
Cell culture and transfection
Human breast cancer MCF7 cells, hepatoma Hep3B cells, hepatoblastoma HepG2 cells, and human embryonic kidney HEK293T cells were maintained in Dulbecco's modified Eagle's medium (Nissui, Tokyo, Japan) supplemented with 10% FBS, and L-glutamine at 371C in an atmosphere containing 5% CO 2 . In some cases, cells were exposed to DOX, 10 J/m 2 UV irradiation, or 5 mM MG132 (Peptide Institute, Osaka, Japan). For transfection of plasmids into the cells, we used the FuGENE6 transfection reagent (Roche, Indianapolis, IN, USA) according to the manufacturer's protocol. The amount of plasmid DNA in each transfection was kept constant by the addition of an appropriate amount of empty expression vector.
siRNA transfections
We designed the following siRNA duplexes within the open reading frame of Siah-1L to knock down Siah-1L. The siRNA duplexes were synthesized and purified by Qiagen Inc. (Cambridge, MA, USA). Siah-1L target sequence was as follows: siSiah-1L, 5 0 -AACTCCTGCCTCCTTATGTATTT-3 0 . The nonsilencing siRNA (control siRNA) was as follows: siCTR, 5 0 -AAGAGCCGTCAGACTGCTACA-3 0 . For transient transfections, cells were seeded at a density of 40-50% in 60 mm diameter plates. The following day, transfections of siRNAs were performed by using Lipofectamine 2000 reagent (Invitrogen), according to the manufacturer's recommended protocol.
Preparation of RNA and RT-PCR
Total RNA was extracted using Sepasol-RNA I Super (Nacalai Tesque, Kyoto, Japan) according to the manufacturer's protocol. RT-PCR was performed using the One Step RNA PCR Kit (Takara, Tokyo, Japan) according to the manufacturer's protocol. The PCR primers for amplification of Siah-1L, Siah-1, and GAPDH were as follows: Siah-1L-3S, 5 0 -GGTTATAATTATTTTTCTCCTGCCTCC-3 0 and Siah-1&1L-512AS, 5 0 -AGTCAACAGCACCAGGAAGA-3 0 ; Siah-1-minus18S, 5 0 -CGCTCTCCGCCCACAGAAAT-3 0 and Siah-1&1L-512AS; GAPDH-1S, 5 0 -ATGGGGAAGGTGAAGGT CGG-3 0 and GAPDH-837AS, 5 0 -TGGAGGGATCTCGCTC CTGG-3 0 .
Western blot analyses
Protein samples were diluted in 2 Â sodium dodecyl sulfate (SDS) sample buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 5% b-mercaptoethanol, 10% glycerol, and 0.002% bromophenol blue). Samples were separated by 10% SDS-polyacrylamide gel electrophoresis (PAGE). After electrotransfer, polyvinylidene difluoride membranes were probed with primary antibodies and secondary antibodies conjugated to HRP. The antibodies used in these experiments were anti-b-catenin (Transduction Laboratories, Lexington, KY, USA), anti-p53 (Ab-6) (Calbiochem), anti-c-Myc (9E10) (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), anti-FLAG M2 (Sigma, St Louis, MO, USA), anti-a-actin (Sigma), and goat 
Reporter assays
To determine Tcf/LEF activity, subconfluent cells were transfected with a reporter construct (pTCF7wt-Luc or pTCF7mut-Luc) and various expression plasmids. A thymidine kinase (TK)-expressing vector (pRL-TK; Promega, Madison, WI, USA) was included as an internal control for transfection efficiency. After 30 h, the cells were lysed and both the luciferase and TK activities were determined using a luciferase assay kit (Promega). Tcf/LEF reporter activities were normalized relative to TK activities and were presented as mean7s.d. from at least three independent experiments.
Evaluation of cell death
MCF7 and Hep3B cells were grown on plastic dishes as monolayers. Cells were transfected with pEGFP-C1 (BD Biosciences Clontech) and various expression plasmids encoding Siah-1L, Siah-1, or Siah-1DRING or empty vector (CTR) for 12 h, followed by treatment with DOX. After 48 h, the GFP-positive cells were counted using a Zeiss AxioVert200 (Zeiss, Hallbergmoos, Germany). The histogram is presented as the average7s.d. of three independent experiments, and the relative survival rate was determined by normalizing to the number of GFP-positive cells transfected with empty vector.
Abbreviations APC, adenomatous polyposis coli; GSK3b, glycogen synthase kinase 3b; SIP, Siah interacting protein; HCC, hepatocellular carcinoma; RT-PCR, reverse-transcriptase polymerase chain reaction; DOX, doxorubicin; siRNA, short interfering RNA; Tcf, T-cell factors; LEF, lymphocyte enhancer-binding factor; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; TK, thymidine kinase.
